MEDPRIN

Medprin (301033.SZ) sits flat at CNY 52.29, below its 200‑day MA and peer P/Es, signaling investor doubt and a call for transparent strategy to revive growth.

Medprin (301033.SZ) reports steady price, rising revenue, and a strategic acquisition in regenerative‑medicine, positioning it for future growth.